Reinmuth, Niels and Paz-Ares, Luis and Chen, Yuanbin and Hotta, Katsuyuki and Trukhin, Dmytro and Statsenko, Galina and Hochmair, Maximilian J and Özgüroğlu, Mustafa and LI, Jun Ho and Voitko, Oleksandr and Poltoratskiy, Artem and Ponce, Santiago and Verderame, Francesco and Havel, Libor and Bondarenko, Igor and Kazarnowicz, Andrzej and Losonczy, György and Conev, Nicolay V and Armstrong, Jon and Byrne, Natalie and Shire, Norah and Jiang, Haiyi and Goldman, Jonathan and Alt, Jürgen (2020) Caspian: Os Results from a Randomised Phase 3 Study of First-Line Durvalumab ± Tremelimumab + Chemotherapy in ES-SCLC. Oncology Research and Treatment, V. 43 (s. 1). p. 115. ISSN 2296-5270 (Print); 2296-5262 (Online)
|
Text
399 Caspian Os Results from a Randomised Phase 3.pdf Download (1MB) | Preview |
Abstract
Immune checkpoint blockade targeting the PD-1/PD-L1 pathway in combination with platinum-based chemotherapy (CT) has demonstrated improved clinical outcomes in patients (pts) with extensive-stage small-cell lung cancer (ES-SCLC). Durvalumab ± Tremelimumab in combination with etoposide and platinum-based CT (EP) as first-line treatment for pts with ES-SCLC. Results will be presented at WCLC 2019 including OS, key secondary endpoints, safety and tolerability.
| Item Type: | Article |
|---|---|
| Additional Information: | https://www.karger.com/Article/Abstract/506491 34. Deutscher Krebskongress informativ. innovativ. integrativ. Optimale Versorgung für alle. Berlin, 19.-22. Februar 2020: Abstracts https://doi.org/10.1159/000506491 WOS:000517158700280 |
| Subjects: | Oncology |
| Divisions: | Departments > Department of Oncology and Medical Radiology |
| Depositing User: | Елена Шрамко |
| Date Deposited: | 21 Apr 2020 08:15 |
| Last Modified: | 21 Apr 2020 08:15 |
| URI: | http://repo.dma.dp.ua/id/eprint/5248 |
Actions (login required)
 |
View Item |
